Treatment of Alzheimer’s Disease

doi:10.1017/9781108985055.021

Chapter 21 - Treatment of Alzheimer’s Disease

from Section 3 - Treatment of the Dementias

Published online by Cambridge University Press: 17 November 2025

Jeffrey L. Cummings

Edited by

Bruce L. Miller and

Bradley F. Boeve

Show author details

Bruce L. Miller: Affiliation:
University of California, San Francisco
Bradley F. Boeve: Affiliation:
Mayo Clinic, Minnesota

Book contents

Get access

Summary

Treatment of Alzheimer’s disease (AD) requires a complex interaction among the patient and care partner, clinician, and health care system. Pharmacotherapy for AD includes aducanumab for patients with mild cognitive impairment mild AD dementia due to AD. Cholinesterase inhibitors are available for mild, moderate, and severe AD dementia and memantine is indicated for patients with moderate and severe AD dementia. Neuropsychiatric symptoms – agitation, psychosis, depression, apathy, insomnia – are common in AD and can be managed with psychotropic agents. Most use of psychotropics is off label and based on the phenotypic similarity between the symptoms occurring in AD and those occurring in disorders with approved indications. The first disease modifying agents for AD are moving toward clinical use in prodromal AD/mild AD dementia. These agents will make new demands on clinicians, health care systems, and patients and their care partners. Pharmacotherapy of AD is combined with recommendations for a brain-healthy lifestyle and care of the care partner.

Keywords

Alzheimer’s disease pharmacotherapy cognitive enhancers agitation psychosis brain health suvorexant aducanumab

Information

Type: Chapter
Information: The Behavioral Neurology of Dementia , pp. 355 - 372

DOI: https://doi.org/10.1017/9781108985055.021 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Alzheimer’s Disease International. From Plan to Impact III. Maintaining Dementia as a Priority in Unprecedented Times. London: Alzheimer’s Disease International, 2020.Google Scholar

2020 Alzheimer’s disease facts and figures. Alzheimer Dement. 2020;16:391–460.10.1002/alz.12068CrossRef Google Scholar

Aisen, PS, Cummings, J, Jack, CR Jr, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017;9(1):60.CrossRef Google Scholar PubMed

Jack, CR Jr, Bennett, DA, Blennow, K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–562.10.1016/j.jalz.2018.02.018CrossRef Google Scholar

Bateman, RJ, Xiong, C, Benzinger, TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804.10.1056/NEJMoa1202753CrossRef Google Scholar PubMed

Dubois, B, Hampel, H, Feldman, HH, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292–323.CrossRef Google Scholar PubMed

Vellas, B, Gauthier, S, Allain, H, et al. Consensus statement on dementia of Alzheimer type in the severe stage. J Nutr Health Aging. 2005;9(5):330–338.Google Scholar PubMed

Cummings, J. Drug development for psychotropic, cognitive-enhancing, and disease-modifying treatments for Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2021;33(1):3–13.10.1176/appi.neuropsych.20060152CrossRef Google Scholar PubMed

Cummings, J, Lee, G, Ritter, A, et al. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020;6(1):e12050.CrossRef Google Scholar PubMed

Budd Haeberlein, S, Aisen, PS, Barkhof, F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9(2):197–210.CrossRef Google Scholar PubMed

Sabbagh, MN, Cummings, J. Open peer commentary to “Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen December 2019.” Alzheimers Dement. 2020;17(4):1702–1703.Google Scholar PubMed

Cummings, J, Rabinovici, GD, Atri, A, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9(2):221–230.10.14283/jpad.2022.34CrossRef Google Scholar PubMed

Swanson, CJ, Zhang, Y, Dhadda, S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021;13(1):80–94.10.1186/s13195-021-00813-8CrossRef Google Scholar PubMed

van Dyck, CH, Swanson, CJ, Aisen, P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21.10.1056/NEJMoa2212948CrossRef Google Scholar PubMed

Cummings, J, Apostolova, L, Rabinovici, GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362–377.10.14283/jpad.2023.30CrossRef Google Scholar PubMed

Mintun, MA, Lo, AC, Duggan Evans, C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–1704.10.1056/NEJMoa2100708CrossRef Google Scholar PubMed

Sperling, RA, Jack, CR Jr, Black, SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367–385.10.1016/j.jalz.2011.05.2351CrossRef Google Scholar PubMed

VandeVrede, L, Gibbs, DM, Koestler, M, et al. Symptomatic amyloid-related imaging abnormalities in an APOE epsilon4/epsilon4 patient treated with aducanumab. Alzheimers Dement (Amst). 2020;12(1):e12101.Google Scholar

Liu, J, Hlavka, J, Hillestad, R, et al. Assessing the preparedness of the US healthcare system infrastructure for an Alzheimer’s treatment. [Research report] RAND Corporation., 2017.10.7249/RR2272CrossRef Google Scholar

Atri, A. The Alzheimer’s disease clinical spectrum: diagnosis and management. Med Clin North Am. 2019;103(2):263–293.10.1016/j.mcna.2018.10.009CrossRef Google Scholar PubMed

Cummings, JL, Morstorf, T, Zhong, K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37.10.1186/alzrt269CrossRef Google Scholar PubMed

Wang, X, Sun, G, Feng, T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. 2019;29(10):787–803.10.1038/s41422-019-0216-xCrossRef Google Scholar PubMed

Martins, M, Silva, R, M, MMP, et al. Marine natural products, multitarget therapy and repurposed agents in Alzheimer’s disease. Pharmaceuticals (Basel). 2020;13(9).10.3390/ph13090242CrossRef Google Scholar PubMed

Levine, SZ, Yoshida, K, Goldberg, Y, et al. Linking the Mini-Mental State Examination, the Alzheimer’s Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil. Evid Based Ment Health. 2021;24(2):56–61.10.1136/ebmental-2020-300184CrossRef Google Scholar PubMed

Rogers, SL, Doody, RS, Mohs, RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158(9):1021–1031.10.1001/archinte.158.9.1021CrossRef Google Scholar PubMed

Tan, CC, Yu, JT, Wang, HF, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41(2):615–631.10.3233/JAD-132690CrossRef Google Scholar PubMed

Grossberg, GT, Schmitt, FA, Meng, X, et al. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2010;25(8):627–633.10.1177/1533317510385808CrossRef Google Scholar PubMed

Cummings, J, Ritter, A, Zhong, K. Clinical trials for disease-modifying therapies in Alzheimer’s disease: a primer, lessons learned, and a blueprint for the future. J Alzheimers Dis. 2018;64(s1):S3–S22.10.3233/JAD-179901CrossRef Google Scholar

Dou, KX, Tan, MS, Tan, CC, et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther. 2018;10(1):126.10.1186/s13195-018-0457-9CrossRef Google Scholar PubMed

Winblad, B, Engedal, K, Soininen, H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57(3):489–495.CrossRef Google Scholar PubMed

Rodda, J, Morgan, S, Walker, Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer’s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr. 2009;21(5):813–824.10.1017/S1041610209990354CrossRef Google Scholar PubMed

Cummings, JL, Schneider, L, Tariot, PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am J Psychiatry. 2004;161(3):532–538.CrossRef Google Scholar PubMed

Tariot, PN, Farlow, MR, Grossberg, GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–324.CrossRef Google Scholar PubMed

Grossberg, GT, Manes, F, Allegri, RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs. 2013;27(6):469–478.10.1007/s40263-013-0077-7CrossRef Google Scholar PubMed

Atri, A, Hendrix, SB, Pejovic, V, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7(1):28.10.1186/s13195-015-0109-2CrossRef Google Scholar PubMed

Farlow, MR, Salloway, S, Tariot, PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234–1251.CrossRef Google Scholar PubMed

Cummings, J, Froelich, L, Black, SE, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33(5):341–353.10.1159/000340056CrossRef Google Scholar

Seshadri, S, Beiser, A, Selhub, J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002;346(7):476–483.10.1056/NEJMoa011613CrossRef Google Scholar PubMed

Douaud, G, Refsum, H, de Jager, CA, et al. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A. 2013;110(23):9523–9528.10.1073/pnas.1301816110CrossRef Google Scholar PubMed

de Jager, CA, Oulhaj, A, Jacoby, R, et al. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry. 2012;27(6):592–600.10.1002/gps.2758CrossRef Google Scholar PubMed

Sakamoto, T, Cansev, M, Wurtman, RJ. Oral supplementation with docosahexaenoic acid and uridine-5’-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. 2007;1182:50–59.10.1016/j.brainres.2007.08.089CrossRef Google Scholar PubMed

Scheltens, P, Kamphuis, PJ, Verhey, FR, et al. Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimers Dement. 2010;6(1):1–10 e1.10.1016/j.jalz.2009.10.003CrossRef Google Scholar PubMed

Scheltens, P, Twisk, JW, Blesa, R, et al. Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J Alzheimers Dis. 2012;31(1):225–236.10.3233/JAD-2012-121189CrossRef Google Scholar PubMed

Soininen, H, Solomon, A, Visser, PJ, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16(12):965–975.CrossRef Google Scholar PubMed

Soininen, H, Solomon, A, Visser, PJ, et al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimers Dement. 2021;17(1):29–40.10.1002/alz.12172CrossRef Google Scholar PubMed

Brodaty, H, Connors, MH, Xu, J, et al. Predictors of institutionalization in dementia: a three year longitudinal study. J Alzheimers Dis. 2014;40(1):221–226.10.3233/JAD-131850CrossRef Google Scholar PubMed

Connors, MH, Seeher, K, Teixeira-Pinto, A, et al. Dementia and caregiver burden: a three-year longitudinal study. Int J Geriatr Psychiatry. 2020;35(2):250–258.10.1002/gps.5244CrossRef Google Scholar PubMed

Cummings, J, Lai, TJ, Hemrungrojn, S, et al. Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer’s disease and dementia with Lewy bodies. CNS Neurosci Ther. 2016;22(3):159–166.10.1111/cns.12484CrossRef Google Scholar PubMed

Cummings, JL, Schneider, E, Tariot, PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67(1):57–63.CrossRef Google Scholar PubMed

Grossberg, GT, Kohegyi, E, Mergel, V, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer’s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2020;28(4):383–400.CrossRef Google Scholar PubMed

Ballard, C, Banister, C, Khan, Z, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018;17(3):213–222.10.1016/S1474-4422(18)30039-5CrossRef Google Scholar PubMed

Cummings, J, Ballard, C, Tariot, P, et al. Pimavanserin: potential treatment for dementia-related psychosis. J Prev Alzheimers Dis. 2018;5(4):253–258.10.14283/jpad.2018.29CrossRef Google Scholar PubMed

Herring, WJ, Ceesay, P, Snyder, E, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer’s disease dementia and insomnia: a randomized trial. Alzheimers Dement. 2020;16(3):541–551.10.1002/alz.12035CrossRef Google Scholar PubMed

Porsteinsson, AP, Keltz, MA, Smith, JS. Role of citalopram in the treatment of agitation in Alzheimer’s disease. Neurodegener Dis Manag. 2014;4(5):345–349.10.2217/nmt.14.35CrossRef Google Scholar PubMed

Cummings, J, Ritter, A, Rothenberg, K. Advances in management of neuropsychiatric syndromes in neurodegenerative diseases. Curr Psychiatry Rep. 2019;21(8):79.10.1007/s11920-019-1058-4CrossRef Google Scholar PubMed

Rosenberg, PB, Lanctot, KL, Drye, LT, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013;74(8):810–816.10.4088/JCP.12m08099CrossRef Google Scholar PubMed

Cummings, J, Pinto, LC, Cruz, M, et al. Criteria for psychosis in major and mild neurocognitive disorders: International Psychogeriatric Association (IPA) consensus clinical and research definition. Am J Geriatr Psychiatry. 2020;28(12):1256–1269.10.1016/j.jagp.2020.09.002CrossRef Google Scholar PubMed

Cummings, J, Isaacson, S, Mills, R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540.10.1016/S0140-6736(13)62106-6CrossRef Google Scholar PubMed

Stern, Y, Albert, M, Brandt, J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer’s disease: prospective analyses from the Predictors Study. Neurology. 1994;44(12):2300–2307.10.1212/WNL.44.12.2300CrossRef Google Scholar PubMed

Lopez, OL, Brenner, RP, Becker, JT, et al. EEG spectral abnormalities and psychosis as predictors of cognitive and functional decline in probable Alzheimer’s disease. Neurology. 1997;48(6):1521–1525.10.1212/WNL.48.6.1521CrossRef Google Scholar PubMed

Yeh, TC, Tzeng, NS, Li, JC, et al. Mortality risk of atypical antipsychotics for behavioral and psychological symptoms of dementia: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials. J Clin Psychopharmacol. 2019;39(5):472–478.10.1097/JCP.0000000000001083CrossRef Google Scholar PubMed

Cummings, JL, Lyketsos, CG, Peskind, ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–1254.10.1001/jama.2015.10214CrossRef Google Scholar PubMed

Herrmann, N, Ruthirakuhan, M, Gallagher, D, et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer’s disease. Am J Geriatr Psychiatry. 2019;27(11):1161–1173.10.1016/j.jagp.2019.05.002CrossRef Google Scholar PubMed

Wang, LY, Shofer, JB, Rohde, K, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry. 2009;17(9):744–751.10.1097/JGP.0b013e3181ab8c61CrossRef Google Scholar PubMed

Sano, M, Cummings, J, Auer, S, et al. Agitation in cognitive disorders: progress in the International Psychogeriatric Association consensus clinical and research definition. Int Psychogeriatr. 2024;36(4);238–250.10.1017/S1041610222001041CrossRef Google Scholar PubMed

Cummings, J, Sano, M, Auer, S, et al. Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm. Int Psychogeriatr. 2024;36(4):251–262.10.1017/S104161022200103XCrossRef Google Scholar PubMed

Porsteinsson, AP, Drye, LT, Pollock, BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–691.10.1001/jama.2014.93CrossRef Google Scholar PubMed

Ehrhardt, S, Porsteinsson, AP, Munro, CA, et al. Escitalopram for agitation in Alzheimer’s disease (S-CitAD): methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimers Dement. 2019;15(11):1427–1436.10.1016/j.jalz.2019.06.4946CrossRef Google Scholar PubMed

Zhu, CW, Grossman, HT, Sano, M. Why do they just sit? Apathy as a core symptom of Alzheimer disease. Am J Geriatr Psychiatry. 2019;27(4):395–405.10.1016/j.jagp.2018.12.013CrossRef Google Scholar PubMed

Miller, DS, Robert, P, Ereshefsky, L, et al. Diagnostic criteria for apathy in neurocognitive disorders. Alzheimers Dement. 2021;17(12):1892–1904.10.1002/alz.12358CrossRef Google Scholar PubMed

Cummings, J. The Neuropsychiatric Inventory: development and applications. J Geriatr Psychiatry Neurol. 2020;33(2):73–84.10.1177/0891988719882102CrossRef Google Scholar

Scherer, RW, Drye, L, Mintzer, J, et al. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018;19(1):46.10.1186/s13063-017-2406-5CrossRef Google Scholar PubMed

Ruthirakuhan, MT, Herrmann, N, Abraham, EH, et al. Pharmacological interventions for apathy in Alzheimer’s disease. Cochrane Database Syst Rev. 2018;5:CD012197.Google Scholar PubMed

Borges, CR, Poyares, D, Piovezan, R, et al. Alzheimer’s disease and sleep disturbances: a review. Arq Neuropsiquiatr. 2019;77(11):815–824.10.1590/0004-282x20190149CrossRef Google Scholar PubMed

Peter-Derex, L, Yammine, P, Bastuji, H, et al. Sleep and Alzheimer’s disease. Sleep Med Rev. 2015;19:29–38.10.1016/j.smrv.2014.03.007CrossRef Google Scholar PubMed

Ju, YE, Lucey, BP, Holtzman, DM. Sleep and Alzheimer disease pathology – a bidirectional relationship. Nat Rev Neurol. 2014;10(2):115–119.CrossRef Google Scholar PubMed

Wang, C, Holtzman, DM. Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors. Neuropsychopharmacology. 2020;45(1):104–120.10.1038/s41386-019-0478-5CrossRef Google Scholar PubMed

Leber, P. Guidelines for the clinical evaluation of antidementia drugs. [First draft. Technical report.] FDA Neuro-Pharm Group, 1990.Google Scholar

Scott, LJ. Lemborexant: first approval. Drugs. 2020;80(4):425–432.10.1007/s40265-020-01276-1CrossRef Google Scholar PubMed

Zee, PC, Vitiello, MV. Circadian rhythm sleep disorder: irregular sleep wake rhythm type. Sleep Med Clin. 2009;4(2):213–218.10.1016/j.jsmc.2009.01.009CrossRef Google Scholar PubMed

Holth, JK, Fritschi, SK, Wang, C, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019;363(6429):880–884.10.1126/science.aav2546CrossRef Google Scholar PubMed

Camargos, EF, Louzada, LL, Quintas, JL, et al. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014;22(12):1565–1574.10.1016/j.jagp.2013.12.174CrossRef Google Scholar PubMed

Kaczynski, A, Michalowsky, B, Eichler, T, et al. Comorbidity in dementia diseases and associated health care resources utilization and cost. J Alzheimers Dis. 2019;68(2):635–646.10.3233/JAD-180896CrossRef Google Scholar PubMed

Bonner, LM, Hanson, A, Robinson, G, et al. Care management to promote treatment adherence in patients with cognitive impairment and vascular risk factors: a demonstration project. J Prev Alzheimers Dis. 2018;5(1):36–41.10.14283/jpad.2017.28CrossRef Google Scholar PubMed

Smets, T, Onwuteaka-Philipsen, BBD, Miranda, R, et al. Integrating palliative care in long-term care facilities across Europe (PACE): protocol of a cluster randomized controlled trial of the “PACE Steps to Success” intervention in seven countries. BMC Palliat Care. 2018;17(1):47.CrossRef Google Scholar PubMed

American Geriatrics Society Ethics C, Clinical P, Models of Care C. American Geriatrics Society feeding tubes in advanced dementia position statement. J Am Geriatr Soc. 2014;62(8):1590–1593.10.1111/jgs.12924CrossRef Google Scholar

Cuffaro, L, Di Lorenzo, F, Bonavita, S, et al. Dementia care and COVID-19 pandemic: a necessary digital revolution. Neurol Sci. 2020;41(8):1977_1979.10.1007/s10072-020-04512-4CrossRef Google Scholar PubMed

Iaboni, A, Cockburn, A, Marcil, M, et al. Achieving safe, effective, and compassionate quarantine or isolation of older adults with dementia in nursing homes. Am J Geriatr Psychiatry. 2020;28(8):835–838.10.1016/j.jagp.2020.04.025CrossRef Google Scholar PubMed

Wong, AH, Roppolo, LP, Chang, BP, et al. Management of agitation during the COVID-19 pandemic. West J Emerg Med. 2020;21(4):795–800.10.5811/westjem.2020.5.47789CrossRef Google Scholar PubMed

Koralnik, IJ, Tyler, KL. COVID-19: a global threat to the nervous system. Ann Neurol. 2020;88(1):1–11.10.1002/ana.25807CrossRef Google Scholar PubMed

Ngandu, T, Lehtisalo, J, Solomon, A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–2263.10.1016/S0140-6736(15)60461-5CrossRef Google Scholar

De la Rosa, A, Olaso-Gonzalez, G, Arc-Chagnaud, C, et al. Physical exercise in the prevention and treatment of Alzheimer’s disease. J Sport Health Sci. 2020;9(5):394–404.10.1016/j.jshs.2020.01.004CrossRef Google Scholar PubMed

Boyle, PA, Buchman, AS, Barnes, LL, et al. Effect of a purpose in life on risk of incident Alzheimer disease and mild cognitive impairment in community-dwelling older persons. Arch Gen Psychiatry. 2010;67(3):304–310.CrossRef Google Scholar PubMed

Wingo, AP, Wingo, TS, Fan, W, et al. Purpose in life is a robust protective factor of reported cognitive decline among late middle-aged adults: the Emory Healthy Aging Study. J Affect Disord. 2020;263:310–317.10.1016/j.jad.2019.11.124CrossRef Google Scholar PubMed

Pistollato, F, Iglesias, RC, Ruiz, R, et al. Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer’s disease: a focus on human studies. Pharmacol Res. 2018;131:32–43.10.1016/j.phrs.2018.03.012CrossRef Google Scholar PubMed

Morris, MC, Tangney, CC, Wang, Y, et al. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015;11(9):1015–1022.10.1016/j.jalz.2015.04.011CrossRef Google Scholar PubMed

Diniz, BS, Butters, MA, Albert, SM, et al. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202(5):329–335.10.1192/bjp.bp.112.118307CrossRef Google Scholar PubMed

Lou, Q, Liu, S, Huo, YR, et al. Comprehensive analysis of patient and caregiver predictors for caregiver burden, anxiety and depression in Alzheimer’s disease. J Clin Nurs. 2015;24(17-18):2668–2678.10.1111/jocn.12870CrossRef Google Scholar PubMed

Piersol, CV, Canton, K, Connor, SE, et al. Effectiveness of interventions for caregivers of people with Alzheimer’s disease and related major neurocognitive disorders: a systematic review. Am J Occup Ther. 2017;71(5):7105180020p1–7105180020p10.10.5014/ajot.2017.027581CrossRef Google Scholar PubMed

Cummings, J, Zhou, Y, Lee, G, et al. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2):e12385.10.1002/trc2.12385CrossRef Google Scholar PubMed

Accessibility standard: WCAG 2.1 AA

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

The HTML of this chapter complies with version 2.1 of the Web Content Accessibility Guidelines (WCAG), covering newer accessibility requirements and improved user experiences and achieves the intermediate (AA) level of WCAG compliance, covering a wider range of accessibility requirements.

Content Navigation

Table of contents navigation
Allows you to navigate directly to chapters, sections, or non‐text items through a linked table of contents, reducing the need for extensive scrolling.

Index navigation
Provides an interactive index, letting you go straight to where a term or subject appears in the text without manual searching.

Reading Order & Textual Equivalents

Single logical reading order
You will encounter all content (including footnotes, captions, etc.) in a clear, sequential flow, making it easier to follow with assistive tools like screen readers.

Short alternative textual descriptions
You get concise descriptions (for images, charts, or media clips), ensuring you do not miss crucial information when visual or audio elements are not accessible.

Visual Accessibility

Use of colour is not sole means of conveying information
You will still understand key ideas or prompts without relying solely on colour, which is especially helpful if you have colour vision deficiencies.

Structural and Technical Features

ARIA roles provided
You gain clarity from ARIA (Accessible Rich Internet Applications) roles and attributes, as they help assistive technologies interpret how each part of the content functions.